A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

August 30, 2021

Primary Completion Date

July 3, 2023

Study Completion Date

July 3, 2023

Conditions
Stomach NeoplasmsEsophageal Neoplasms
Interventions
DRUG

Amivantamab

Amivantamab will be administered intravenously.

Trial Locations (10)

104 0045

National Cancer Center Hospital, Chūōku

277 8577

National Cancer Center Hospital East, Kashiwa

362-0806

Saitama Cancer center, Kitaadachi-gun

951-8566

Niigata Cancer Center Hospital, Niigata

060-8648

Hokkaido University Hospital, Sapporo

980 8574

Tohoku University Hospital, Sendai

565-0871

Osaka University Hospital, Suita-shi

113 8677

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo

135 8550

The Cancer Institute Hospital of JFCR, Tokyo

232 0024

Yokohama City University Medical Center, Yokohama

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT04945733 - A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer | Biotech Hunter | Biotech Hunter